Home > Press > Iran Produces 1st Anti-Cancer Nano Drug
Abstract:
Iranian scientists have developed the country's first anti-cancer drug using nanotechnology, an official announced.
"The first anti-cancer medicine was produced in Iran," Head of the Public Relations of the Presidential Office's Technological Cooperation Department Amir Khanian said in January.
He also said that the Iranian scientists have produced 18 biotech drugs and are carrying out research on another 29 biotech medicines.
Iran has taken wide strides in science and technology, particularly in medical and medicinal fields, in recent years.
The country has already mass-produced Doxorubicin - a non-carcinogenic drug - used in lung and breast cancer cases and made based on nano-liposomes technique. The drug with higher efficiency needs lower times for use and naturally lessens side effects, including vascular and heart complications.
Iran has also produced two other non-carcinogenic medicines Paclitaxel for breast and ovarian cancer and oxaliplatin for colon cancer.
In September, Iranian researchers from Lorestan University succeeded in designing a new type of drug delivery system for anti-cancer drugs by using linear dendritic polymers and iron nanoparticles.
Hybrid nanocomposites were used in this drug delivery system. Carbon nanotubes were also used in the system to make possible the quick passage through cellular walls.
Among the significant characteristic of the research was hybridization of a series of nanomaterials in a system to use all their properties in the elimination of cancerous cells.
Iran is among the very few countries which have developed a remedy for the most fearsome disease in the human community, known as AIDS. In 2007, Iranian scientists found a safe and effective cure for the dreaded virus, AIDS. This medicine made up of herbal and chemical components works to build immunity and enhance the quality of life of both AIDS and HIV-positive patients with no proven side effects.
Five years later, Iran helped Mali control and contain HIV infection across the African nation. A senior official of Iran's Red Crescent Society announced in August 2012 that HIV-infected patients in Mali had shown positive reactions to the Iran-made AIDS curing drug, Imod, in the course of their treatment.
"We have been witnessing highly positive results of Iran-made Imod drug on AIDS patients in Mali during the last two years," Deputy of RCS for Health, Treatment and Rehabilitation Abdolreza Shahrezayee told FNA on August 31, 2012.
He underlined Iran's extended health and treatment services in Mali, and said HIV-positive patients were being cured by Imod in RCS's polyclinic.
####
For more information, please click here
Copyright © Fars News Agency
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Discoveries
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||